{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:16:40Z","timestamp":1771431400927,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.revmed.2025.08.006","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:06:30Z","timestamp":1756292790000},"page":"70-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Poumon et scl\u00e9rodermie syst\u00e9mique"],"prefix":"10.1016","volume":"47","author":[{"given":"\u00c9ric","family":"Hachulla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2025.08.006_bib0185","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.revmed.2025.08.006_bib0190","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.08.006_bib0195","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.lpm.2014.08.002","article-title":"Interstitial lung disease in systemic sclerosis","volume":"43","author":"Wells","year":"2014","journal-title":"Presse Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0200","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12016-009-8194-2","article-title":"Scleroderma lung disease","volume":"40","author":"Le Pavec","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.revmed.2025.08.006_bib0205","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13023-021-01844-y","article-title":"French recommendations for the management of systemic sclerosis","volume":"16","author":"Hachulla","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2025.08.006_bib0210","first-page":"1182","article-title":"2023\u00a0American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2025.08.006_bib0215","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2025.08.006_bib0220","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1148\/radiol.2322031223","article-title":"CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia","volume":"232","author":"Desai","year":"2004","journal-title":"Radiology"},{"key":"10.1016\/j.revmed.2025.08.006_bib0225","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0230","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"Moore","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2025.08.006_bib0235","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.08.006_bib0240","series-title":"Protocole national de diagnostic et de soins\u00a0\u2013\u00a0scl\u00e9rodermie syst\u00e9mique","year":"2022"},{"key":"10.1016\/j.revmed.2025.08.006_bib0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023\u00a0update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.08.006_bib0250","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An Official American Thoracic Society Clinical Practice Guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0255","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231159712","article-title":"Systemic sclerosis associated interstitial lung disease: a survey of current practices in France","volume":"15","author":"Nicolas","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.revmed.2025.08.006_bib0260","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0265","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0270","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2025.08.006_bib0275","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs. rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2025.08.006_bib0280","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DesiReS): a doubleblind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2025.08.006_bib0285","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0290","doi-asserted-by":"crossref","first-page":"220207","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2025.08.006_bib0295","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2025.08.006_bib0300","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0305","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0310","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100\u00a0weeks: data from a randomized controlled trial","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.revmed.2025.08.006_bib0315","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0320","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0325","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2025.08.006_bib0330","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0335","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2025.08.006_bib0340","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.revmed.2023.12.008","article-title":"French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases","volume":"45","author":"Farge","year":"2024","journal-title":"Rev Med Intern"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.revmed.2025.08.006_bib0345","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.rmr.2022.12.014","article-title":"Lung transplantation for systemic sclerosis-associated interstitial lung disease","volume":"40","author":"Le Pavec","year":"2023","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.revmed.2025.08.006_bib0350","doi-asserted-by":"crossref","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2025.08.006_bib0355","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1378\/chest.10-2473","article-title":"Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease","volume":"140","author":"Launay","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2025.08.006_bib0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.chest.2023.08.013","article-title":"Impact of systemic sclerosis-associated interstitial lung disease with and without pulmonary hypertension on survival: a large cohort study of the German network for systemic sclerosis","volume":"165","author":"Moinzadeh","year":"2024","journal-title":"Chest"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325007441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325007441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:41:07Z","timestamp":1771429267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866325007441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0248866325007441"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2025.08.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poumon et scl\u00e9rodermie syst\u00e9mique","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2025.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}